Artiva Biotherapeutics, Inc. ARTV 深 滬
等待開盤 10-20 09:30:00 美东时间
6.01
+3.240
+116.97%
華盛通- 最 高7.36
- 今 開5.59
- 成交量 1.00亿股
- 最 低 5.1401
- 昨 收 2.77
- 總市值 1.47亿
- 52周最高 15.49
- 市盈率 靜 --
- 換手率 410.35%
- 52周最低 1.47
- 委 比 58.25%
- 總股本 2442.58万
- 歷史最高 17.31
- 量 比 22.47
- 振 幅 80.14%
- 歷史最低 1.47
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
今天 10:03
Why Is Artiva Up Today?
Shares of Artiva Biotherapeutics, Inc. are rising Friday after the San Diego-based biotech company shared a milestone regulatory update.
10-18 03:07
Market-Moving News for October 17th
CSX: 3% | CSX shares are trading higher after the company reported better-than-expected Q3 financial results. ARTV: 144% | Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK; Continued
10-17 19:27
Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK; Continued Execution And Enrollment Progress With More Than 20 Patients Treated With AlloNK + Monoclonal Antibody Therapy Across Company-sponsored And Investigator-Initiated Trials In Autoimmune Diseases
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for
10-17 04:08
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Artiva Biotherapeutics received FDA Fast Track Designation for AlloNK® in refractory rheumatoid arthritis (RA), making it the first drug candidate in the deep B-cell depleting category to receive this designation. Over 20 patients have been treated with AlloNK + monoclonal antibody therapy across various autoimmune diseases. The company plans to release translational and safety data in mid-November, highlighting deep B-cell depletion and favorabl...
10-16 20:05
Artiva Biotherapeutics Reports Progress in Clinical Trials
Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q2 earnings. Here is ...
08-29 12:10
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
Artiva Biotherapeutics announced progress in its clinical trials for AlloNK® in autoimmune diseases, including treating the first patient in a global basket trial for refractory rheumatoid arthritis, Sjögren’s disease, and systemic sclerosis. Over a dozen patients have been treated across multiple sites. Initial safety and efficacy data are expected by year-end 2025, with clinical response data in the lead indication anticipated in 1H2026. The co...
08-06 20:05
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
HC Wainwright & Co. Assumes Artiva Biotherapeutics at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Emily Bodnar assumes Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and announces Price Target of $12.
06-11 19:03
